Cardiff Oncology, Inc. CRDF
1.24
(0.04)
(3.13%)
as of 25 Sep
- Market cap
- $99.6M
- P/E
- 0.0×
Follow CRDF
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (94.14%) | (84.84%) | (71.49%) | (102.76%) |
+8 more TTM periods Free account |
|
| (70.89%) | (66.86%) | (57.68%) | (79.65%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(158.75%) | (134.21%) | (103.53%) | (105.62%) | |
Average Days of Receivables |
135.80 | 132.79 | 112.02 | 185.42 | |
Free Cash Flow per Share |
(0.60) | (0.55) | (0.57) | (0.63) | |
Free Cash Flow |
(40.94) | (37.42) | (37.97) | (42.27) | |
Capital Expenditures |
(0.09) | — | (0.04) | (0.04) | |
Piotroski F-Score |
2.00 | 2.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(66.92%) | (46.33%) | (36.57%) | (38.60%) | |
Accounts Receivable Turnover |
1.42 | 1.76 | 1.24 | 1.15 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,108.66% | 6,022.29% | 5,957.67% | 7,993.00% | |
Selling, General and Administrative Expense of Revenue |
3,311.42% | 3,111.62% | 2,398.65% | 2,848.00% | |
Share Based Compensation of Revenue |
1,028.54% | 1,140.57% | 960.03% | 1,127.20% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.02 | 0.84 | 0.83 | 0.84 | |
Depreciation/Fixed assets |
(0.48) | (0.91) | (0.84) | (0.71) | |
Capex/Depreciation |
0.41 | 0.00 | 0.09 | 0.09 | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.60) | (0.55) | (0.57) | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.17 | 0.00 | 0.07 | 0.09 | |
Net Profit Margin |
(7,888.98%) | (8,530.86%) | (7,736.26%) | (10,089.20%) |
Columns are period end dates